References
- Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.
- Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-asso-ciated multidrug resistance in patients' tumors: consensus rec-ommendations. Cancer Res. 1996;56:3010–20.
- Ueda K, Cardaralli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human "MDR-1" gene confers resis-tance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84:3004–8.
- Salmon SE, Dalton WS. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypoth-esis. J Rheumatol Suppl. 1996;44:97–101.
- Chen C, Pollack GM. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm Res. 1999;16:296–301.
- Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Increased expression of multidrug resistance of P-glycoprotein on Th 1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum. 1999;42: 2014–5.
- Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, et al. Transcriptional regulation of multidrug resis-tance-1 gene by interleukin-2 in lymphocytes. Genes Cells. 2004;9:1265–73.
- Tsujimura S, Saito K, Kohno K, Tanaka Y. Fragmented hyaluronan induces transcriptional up-regulation of the multi-drug resistance-1 gene in CD4+ T cells. J Biol Chem. 2006;281:38089–97.
- Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lym-phocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008;67:380–8.
- Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Piel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum. 1995; 38:44–8.
- Tanaka Y, Minami Y, Mine S, Hirano H, Hu CD, Fujimoto H, et al. H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. J Immunol. 1999;163 :6209–16.
- Tanaka Y, Wake A, Horgan KJ, Murakami S, Aso M, Saito K, et al. Distinct phenotype of leukemic T cells with various tissue tropisms. J Immunol. 1997;158:3822–9.
- Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cell. 1994;12: 456–65.
- Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum. 1967;10:357–76.
- Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. Concen-tration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropa-thies. Ann Rheum Dis. 1985;44:817–22.
- Marzio R, Mauel J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol. 1999; 21:565–82.
- Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of the expression of P-glycoprotein on peripheral lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:1676–83.
- Brocq 0, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A, et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with antiTNF alpha. Press Med. 2002;31: 1836–9.
- van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor a blockers can make sense. Ann Rheum Dis. 2003;62:1195–8.
- van Vollenhoven R. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis. 2007;66:849–51.
- Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to eta-nercept: the opposite study. Ann Rheum Dis. 2007;66:893–9.
- Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004;63:1344–6.